市场概况

The clinical trials software market is projected to grow at a CAGR of 11.5% 从 2023 到 2029, reaching a value of $2.33 十亿 2029, up from $1.05 billion in 2022. Clinical trials play a vital role in disease treatment and improving detection, diagnosis, and prevention. The market’s growth is driven by pharmaceutical organizations’ cost reduction demands and technology advancements. Clinical trial software (CTMS) helps manage research activities for contract research organizations (合同研究组织). The global increase in clinical trials necessitates software solutions for easy access to activities. The biopharmaceutical industry has seen changes, with CROs becoming integral to clinical trial services. CTMS streamlines the process. The COVID-19 pandemic accelerated the digitization of trials, leading to increased adoption of digital tools and remote monitoring devices. Cloud computing offers opportunities for market vendors. Virtual trials gain traction with software enabling increased patient enrollment. Virtual patient recruitment software eliminates travel, automates data collection, and enhances engagement. Key players prefer unified platforms. Medidata offers a comprehensive unified platform. IQVIA is a leading pharmaceutical company in cloud computing. Digital tools address cost and timeline challenges. The pandemic prompted software use for vaccine production and trials.

该报告涵盖了市场规模和增长, 分割, 竞争格局, trends and strategies for global clinical trials software market. 它提供了对市场的定量分析，使利益相关者能够利用当前的市场机会. 该报告还根据市场趋势和主要竞争对手的方法确定了最重要的机会和战略细分市场.

市场细分

The market is segmented based on various factors, including deployment, delivery, feature, end-user, and geography.
Deployment: on-enterprises, on-site
Delivery: web-based, SaaS, 本地
Feature: EDC, eCOA/ePRO, eConsent
最终用户: 合同研究组织, bio-pharmaceutical companies, medical device manufacturers, 其他的

Segmentation by Geography
North America – US, 加拿大
Europe – Germany, 法国, 英国, 意大利, 西班牙
APAC – 中国, 日本, 印度, 韩国, 澳大利亚
Latin America – Brazil, 墨西哥, 阿根廷
Middle East & Africa – South Africa, 沙特阿拉伯, 火鸡, UAE

The clinical trial software market is divided into on-enterprises and on-site segments. 在 2022, on-enterprises held the dominant position, 占 78.6% of the market. This is due to the increasing adoption of technology in biopharmaceutical companies and the usage of clinical trial management systems. On-site deployment offers advantages to contracting research organizations, sponsors, and academic and government institutes. Biopharmaceutical companies with their own IT infrastructure find it easier to handle CTMS solutions, reducing costs and timelines.

Web-based delivery was the dominant segment in 2022, 占 44.5% of the market share. Major biopharmaceuticals prefer web-based delivery for seamless data management, analysis, medical writing, and regulatory submission. It enables quick reviews and efficient data collection from participants through internet platforms, reducing errors and confusion. The increasing competitiveness in the biopharma and contract research industries drives the demand for software. Web-based delivery provides faster delivery and is associated with the acceptance of Software-as-a-Service (SaaS) in CTMS.

The global clinical trials software market is further segmented into EDC, eCOA/ePRO, and eConsent. EDC, also known as eCRF, is vital for collecting and analyzing patient data. The increasing demand for participant data and the use of EDC contribute to significant market growth, with a share of 46.6% 在 2022.

CROs accounted for 45.7% of the market share in 2022. They experience high demand for medical research from biopharmaceutical companies, medical device manufacturers, and other authorities. Intense competition, high investments, and low success rates of clinical trials drive the demand for CROs.

North America has the largest market share, with 34.3% 在 2022. This is due to the presence of key market players, a high number of biopharmaceutical companies, and significant research and development expenditure in the region.

Competitive Landscape

The global clinical trial software market is highly competitive due to collaboration, cloud-based platforms, and new solutions. Regional companies in Europe, APAC, and North America are investing in advanced software products, posing a threat to global players. This creates growth opportunities for existing and emerging players. Key companies profiled include Advarra, 公司, ArisGlobal LLC, Axiom Real-Time Metrics Inc., BSI Business Systems Integration AG, Ciwit B.V. (Castor), Clario, 公司, ClinCapture , 公司, Dassault Systemes SE, Datatrak International, 公司. (Fountayn LLC), Datatrial Limited, Dotmatics Limited (Statsols), Florence Healthcare, 公司, Fortress Medical Systems, 有限责任公司, IBM公司, IQVIA Holdings, 公司, Labcorp Drug Development Inc., Medrio, 公司, 甲骨文公司, PAREXEL International Corporation, Reify Health, 公司, Veeva Systems Inc., 除其他外.

报告范围

To analyze and forecast the market size of the global clinical trials software market.
To classify and forecast the global clinical trials software market based on deployment, delivery, feature, 最终用户, geography.
To identify drivers and challenges for the global clinical trials software market.
检查合并等竞争性发展 & 收购, 协议, 合作与伙伴关系, ETC。, in the global clinical trials software market.
To identify and analyze the profile of leading players operating in the global clinical trials software market.

为什么选择这份报告

Gain a reliable outlook of the global clinical trials software market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.